KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia. Iyoda S, Yoshida K, Shoji K, Ito N, et al. Leukemia 2024 Apr 18. doi: 10.1038/s41375-024-02244.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Iyoda S, Yoshida K, Shoji K, Ito N, et al. KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia. Leukemia 2024 Apr 18. doi: 10.1038/s41375-024-02244.
PMID: 38632314